Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S, Jia J, Spicuglia S, Ferrier P, Ceccon M, Giuriato S, Gambacorti-Passerini C, Brousset P, Lamant L, Meggetto F.
Hoareau-Aveilla C, et al.
J Clin Invest. 2015 Sep;125(9):3505-18. doi: 10.1172/JCI78488. Epub 2015 Aug 10.
J Clin Invest. 2015.
PMID: 26258416
Free PMC article.